UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 150

Sortiert nach

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European journal of cancer (1990), 2016-02, Vol.54, p.139-148

2016

Volltextzugriff (PDF)

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

Annals of oncology, 2015-06, Vol.26 (6), p.1223-1229

2015

Volltextzugriff (PDF)

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

European journal of cancer (1990), 2017-08, Vol.81, p.81-89

2017

Volltextzugriff (PDF)

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii496-viii497

2018

Volltextzugriff (PDF)

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Annals of oncology, 2018-10, Vol.29, p.viii404-viii404

2018

Volltextzugriff (PDF)

Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial

Annals of oncology, 2018-10, Vol.29, p.viii667-viii667

2018

Volltextzugriff (PDF)

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Annals of oncology, 2016-02, Vol.27 (2), p.344-352

2016

Volltextzugriff (PDF)

Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial

Annals of oncology, 2018-10, Vol.29, p.viii378-viii379

2018

Volltextzugriff (PDF)

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Annals of oncology, 2018-10, Vol.29, p.viii422-viii422

2018

Volltextzugriff (PDF)

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

Annals of oncology, 2012-05, Vol.23 (5), p.1301-1306

2012

Volltextzugriff (PDF)

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.306-310

2015

Volltextzugriff (PDF)

Phase II trial of thalidomide in renal-cell carcinoma

Annals of oncology, 2002-07, Vol.13 (7), p.1029-1035

2002

Volltextzugriff (PDF)

Exosomes for cancer immunotherapy

Annals of oncology, 2004-01, Vol.15 (suppl-4), p.iv141-iv144

2004

Volltextzugriff (PDF)

Tumor-derived exosomes: a new source of tumor rejection antigens

Vaccine, 2002-12, Vol.20, p.A28-A31

2002

Volltextzugriff (PDF)

505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine

European journal of cancer (1990), 2015-09, Vol.51, p.S104-S105

2015

Volltextzugriff (PDF)

7169 POSTER Study of Dynamic Contrast-enhanced Ultrasound (DCE-US) for the Early Evaluation in Patients Included in Phase II Treated With TKI 258 in Renal Cell Carcinoma

European journal of cancer (1990), 2011, Vol.47, p.S526-S526

2011

Volltextzugriff (PDF)

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC

Annals of oncology, 2010-07, Vol.21 (7), p.1559-1560

2010

Volltextzugriff (PDF)

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

The Journal of experimental medicine, 2001-10, Vol.194 (8), p.1179-1186

2001

Volltextzugriff (PDF)

Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells

The Journal of immunology (1950), 2001-08, Vol.167 (3), p.1795-1802

2001

Volltextzugriff (PDF)

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Journal of translational medicine, 2005-03, Vol.3 (1), p.10-10

2005

Volltextzugriff (PDF)

Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning

Annals of oncology, 2019-10, Vol.30, p.v52

2019

Volltextzugriff (PDF)

165P - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning

Annals of oncology, 2019-10, Vol.30, p.v52-v52

2019

Volltextzugriff (PDF)

Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells

The Journal of immunology (1950), 2004-02, Vol.172 (4), p.2126-2136

2004

Volltextzugriff (PDF)

Malignant effusions and immunogenic tumour-derived exosomes

The Lancet (British edition), 2002-07, Vol.360 (9329), p.295-305

2002

Volltextzugriff (PDF)

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

Nature medicine, 2001-03, Vol.7 (3), p.297-303

2001

Volltextzugriff (PDF)

1 – 25 von 150

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(135)

Publikationsform

Artikel
(149)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1

Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy

Phase II trial of thalidomide in renal-cell carcinoma

Exosomes for cancer immunotherapy

Tumor-derived exosomes: a new source of tumor rejection antigens

505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine

7169 POSTER Study of Dynamic Contrast-enhanced Ultrasound (DCE-US) for the Early Evaluation in Patients Included in Phase II Treated With TKI 258 in Renal Cell Carcinoma

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning

165P - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning

Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells

Malignant effusions and immunogenic tumour-derived exosomes

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

Suchergebnisse filtern